Log in
FREE 15-Day Trial
Intelligent Investor
Intelligent Investor
  1. Home
  2. Research & Advice
  3. Research Tools
  4. Shares
  5. Antisense Therapeutics Limited (ANP)
  6. Company Announcements

Antisense Therapeutics Limited (ASX: ANP) - Announcements

Current share price for ANP : $0.058 0.003 (4.92%)

ASX company news and announcements for Antisense Therapeutics Limited (ANP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Antisense Therapeutics Limited (ANP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Antisense Therapeutics Limited (ANP), please use our Company Announcements tool to search across all ASX-listed companies.

Intelligent Investor free trial for buy hold sell stock recommendations

Latest company announcements for Antisense Therapeutics Limited (ANP)

Search all Announcements
Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg		 Gain/Loss
$52 ATL1103 Project Update - Scientific Publication 31 Aug 2007 1:00PM $0.038 $0.058 $0.059 risen by 52.63%
$52 Preliminary Final Report 2 Aug 2007 4:39PM $0.037 $0.058 $0.059 risen by 56.76%
$52 Appendix 4C - quarterly 24 Jul 2007 10:42AM $0.040 $0.058 $0.059 risen by 45%
$52 Response to ASX Price Query 11 Jul 2007 10:07AM $0.046 $0.058 $0.059 risen by 26.09%
$52 ATL1102 Phase IIa MS Trial Update 22 Jun 2007 9:08AM $0.037 $0.058 $0.059 risen by 56.76%
$52 Commitments Test Entity - Third Quarter Report 20 Apr 2007 9:35AM $0.036 $0.058 $0.059 risen by 61.11%
$52 Further validation for 2nd generation antisense drugs 27 Mar 2007 12:22PM $0.043 $0.058 $0.059 risen by 34.88%
$52 ATL1102 - European Patent Granted 7 Feb 2007 9:49AM $0.053 $0.058 $0.059 risen by 9.43%
$52 ANP/ISIS Extend Development Collaboration 5 Feb 2007 9:47AM $0.055 $0.058 $0.059 risen by 5.45%
$52 Half Yearly Report & Half Year Accounts 30 Jan 2007 3:46PM $0.042 $0.058 $0.059 risen by 38.10%
$52 Phase IIa Multiple Sclerosis Trial Update 25 Jan 2007 10:26AM $0.057 $0.058 $0.059 risen by 1.75%
$52 Commitments Test Entity - Second Quarter Report 24 Jan 2007 10:52AM $0.057 $0.058 $0.059 risen by 1.75%
$52 Response to ASX Query re Share Price 4 Jan 2007 8:59AM $0.050 $0.058 $0.059 risen by 16%
$52 ATL1103 to Prgogress Towards Clinical Development 20 Dec 2006 11:30AM $0.042 $0.058 $0.059 risen by 38.10%
$52 Market Developments 13 Nov 2006 5:26PM $0.036 $0.058 $0.059 risen by 61.11%
$52 Share Placement to Overseas Institutional Investors 13 Nov 2006 10:04AM $0.032 $0.058 $0.059 risen by 81.25%
$52 Commitments Test Entity - First Quarter Report 24 Oct 2006 9:59AM $0.028 $0.058 $0.059 risen by 107.14%
$52 Animal Study Results Support Potential of ATL1102 for MS 11 Oct 2006 9:47AM $0.026 $0.058 $0.059 risen by 123.08%
$52 ATL1002 Phase IIa Multiple Sclerosis Trial Update 4 Oct 2006 10:43AM $0.023 $0.058 $0.059 risen by 152.17%
$52 Lead Compound ATL1102 - Patent Granted in Japan 29 Aug 2006 10:11AM $0.024 $0.058 $0.059 risen by 141.67%
$52 Preliminary Final Report 7 Aug 2006 10:10AM $0.025 $0.058 $0.059 risen by 132%
$52 Commitments Test Entity - Fourth Quarter Report 25 Jul 2006 12:47PM $0.026 $0.058 $0.059 risen by 123.08%
$52 Market Developments 30 Jun 2006 10:02AM $0.026 $0.058 $0.059 risen by 123.08%
$52 Commencement of Dosing of Patients in Phase IIa M.S. Trial 21 Jun 2006 9:31AM $0.025 $0.058 $0.059 risen by 132%
$52 FDA approves the reintroduction of Tysabri 7 Jun 2006 9:45AM $0.032 $0.058 $0.059 risen by 81.25%

651 - 675 of 707 results

Page 27 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.